Company Ticker News September 21, 2021Merck & Co., Inc. (MRK) Management Presents at European Society for Medical Oncology Virtual Congress 2021 (Transcript) 0 0 Share
Press Release September 19, 2021Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10) 0 0 Share
Company Ticker News September 19, 2021Could Pfizer and Merck Be Big Winners With COVID Pills? 0 0 Share
Press Release September 18, 2021Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer 0 0 Share
Press Release September 18, 2021Merck's KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting 0 0 Share
Press Release September 17, 2021Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10) 0 0 Share
Company Ticker News September 14, 2021Merck (MRK) Stock Sinks As Market Gains: What You Should Know 0 0 Share
